Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the similarities between COVID-19 and acute radiation syndrome, highlighting their shared inflammatory responses and suggesting that insights from radiation biology could inform COVID-19 research and treatment approaches; it reports no new clinical results.

This review discusses gene polymorphisms in COVID-19 patients but reports no new clinical findings.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

In this case report, etanercept was observed to effectively resolve symptoms of refractory acrodermatitis continua suppurativa Hallopeau after previous treatments had limited success.

Abatacept may help some people with alopecia areata regrow hair.

In this case report, a patient experienced a recurrence of alopecia areata while undergoing etanercept treatment, suggesting the drug may not effectively prevent this condition's return.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

This study found that betibeglogene autotemcel significantly improved transfusion independence in 89% of patients with transfusion-dependent beta-thalassemia, although the high cost and manufacturing challenges may limit widespread adoption.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

In this study, a patient with Cronkhite-Canada syndrome complicated by severe sepsis and disseminated intravascular coagulation was successfully treated using combined therapies, including recombinant human soluble thrombomodulin, despite the absence of a standard treatment regimen for CCS.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This review explores the complex role of the Innate Immune System in rheumatoid arthritis, highlighting gaps in understanding its functions and interactions with the Adaptive Immune System, offering insights into potential biomarkers and therapeutic strategies for this challenging autoimmune condition.

This review discusses the potential of therapeutic antibodies as an alternative treatment for androgenetic alopecia, highlighting the initial development stages and the need for further validation and optimization of targets like the prolactin receptor and Interleukin-6 receptor.

This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This paper discusses a case of acrodermatitis continua that was resistant to treatment with etanercept, highlighting the therapeutic challenges faced, but reports no new research results.

This study found that combining excimer light at 308 nm with tacrolimus 0.1% was more effective in treating alopecia areata of the scalp compared to excimer light alone, as indicated by a greater reduction in the SALT score and better improvement in Treg function.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.